Press release (July 10th 2007)

PharmaSwiss S.A. expands shareholder base

Contact: R. Stuart Swanson, + 386 31 693 200
or office@pharmaswiss.com or +381 11 3093 921

PHARMASWISS S.A. EXPANDS SHAREHOLDER BASE:
HBM BIOVENTURES AS NEW MINORITY SHAREHOLDER

Zug, July 10th, 2007 --- PharmaSwiss S.A., a Switzerland-based holding company with pharmaceutical businesses across Central and Eastern European countries, Greece and Israel announced the expansion of its shareholder base today. HBM BioVentures, a major investor in pharmaceutical and biotechnology companies worldwide, has become a minority shareholder in PharmaSwiss S.A. Petr Nemec and Stuart Swanson, the two founders of PharmaSwiss S.A., will continue to hold the majority of shares in the company.

"We welcome HBM BioVentures, a large pharma and biotech investor, as a new shareholder", commented Petr Nemec, Founding Partner and CEO of PharmaSwiss S.A.. "With HBM BioVentures as a major investor in our company, we will be in a strong position to continue the growth and expansion of our businesses in Central and Eastern Europe."

"The HBM investment is another confirmation that PharmaSwiss S.A. has become the Third Party Partner of choice for marketing and distribution of research-based pharma and biotech products in Central & Eastern European countries, as well as Greece,” stated Stuart Swanson, Partner and Head of Business Development at PharmaSwiss S.A.

“Through the biotech and pharmaceutical network of HBM BioVentures, as well as via leveraging our newly-expanded financial resources, we will accelerate the growth of our portfolio, and further expand our geographical reach. Strengthened by this investment from HBM, we will intensify our efforts to find new multinational clients and international brands to represent, in-license or purchase.”

Andreas Wicki, CEO of HBM BioVentures, stated that "as a new shareholder in PharmaSwiss S.A. we look forward to substantially contribute to the further growth of its businesses. The pharmaceutical markets in Central and Eastern Europe have enjoyed exciting growth and PharmaSwiss S.A. is well positioned to continue its success story."

About PharmaSwiss S.A.

Founded in 2000, PharmaSwiss S.A. is a 100 million Euro turnover company operating in 14 countries, including Central and Eastern Europe, Greece and Israel. Employing approximately 400 people, the company’s primary activity is full service, third party representation – PharmaSwiss S.A. represents leading pharmaceutical multinationals in countries, or therapeutic areas, where they chose not to maintain a direct presence. The company carries out marketing, promotional, regulatory / pharmacovigilance and other services, as well as distribution, credit collection and logistics activities.

PharmaSwiss S.A. is privileged to represent the products of leading, research-based multinationals like Bristol-Myers Squibb, Wyeth, Astellas, Ferring, Ipsen, Helsinn, Eli Lilly and Amgen, amongst others.

Since establishing its EU GMP-qualified factory in Belgrade in 2006, PharmaSwiss S.A. has launched several of its own products, such as Diclofenac Duo, Cardiopirin (a low-dose, enteric coated aspirin) and Mamavit (a prenatal vitamin). Several other novel medicine launches are planned for the immediate future.

For further information visit www.pharmaswiss.com

About HBM BioVentures

HBM BioVentures invests worldwide in the human medicine, biotechnology and medical technology sectors. As a venture capital company it manages a mature, widely diversified portfolio of private and small-cap public young companies. Investors value HBM BioVentures as an integral part of their healthcare portfolio, giving them access to this newly created investment segment with its high value creation potential.

HBM BioVentures is an active, long-term investor in research and development which finances, accompanies and supports portfolio companies as a key partner. With net assets of over CHF 1 billion, HBM BioVentures is one of the most liquid investments in this sector. Lean structures ensure a competitive cost structure, while wide-ranging expertise, operating industrial experience, highest professional standards and transparency distinguish the company. HBM BioVentures Ltd has a broad shareholder base.

For further information visit www.hbmbioventures.com